التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion. |
| المؤلفون: |
Biagetti, Betina, Araujo-Castro, Marta, Torre, Edelmiro Menéndez, Novoa-Testa, Iría, Cordido, Fernando, Corrales, Eider Pascual, Berrocal, Víctor Rodríguez, Guerrero-Pérez, Fernando, Vicente, Almudena, Percovich, Juan Carlos, Centeno, Rogelio García, González, Laura, García, María Dolores Ollero, Echarri, Ana Irigaray, Rodríguez, María Dolores Moure, Novo-Rodríguez, Cristina, Calatayud, María, Villar-Taibo, Rocío, Bernabéu, Ignacio, Alvarez-Escola, Cristina |
| المصدر: |
European Journal of Endocrinology; Jun2024, Vol. 190 Issue 6, p458-466, 9p |
| مصطلحات موضوعية: |
THERAPEUTICS, ACROMEGALY, SOMATOSTATIN receptors, PROLACTIN, SOMATOTROPIN |
| مستخلص: |
Objective The aim of this study is to compare the response to first-line medical treatment in treatment-naive acromegaly patients with pure growth hormone (GH)-secreting pituitary adenoma (GH-PA) and those with GH and prolactin cosecreting PA (GH&PRL-PA). Design This is a retrospective multicentric study of acromegaly patients followed from 2003 to 2023 in 33 tertiary Spanish hospitals with at least 6 months of first-line medical treatment. Methods Baseline characteristics, first-line medical treatment strategies, and outcomes were analyzed. We employed a multiple logistic regression full model to estimate the impact of some baseline characteristics on disease control after each treatment modality. Results Of the 144 patients included, 72.9% had a GH-PA, and 27.1% had a GH&PRL-PA. Patients with GH&PRL-PA were younger (43.9 ± 15.0 vs 51.9 ± 12.7 years, P <.01) and harboring more frequently macroadenomas (89.7% vs 72.1%, P =.03). First-generation somatostatin receptor ligand (fgSRL) as monotherapy was given to 106 (73.6%) and a combination treatment with fgSRL and cabergoline in the remaining 38 (26.4%). Patients with GH&PRL-PA received more frequently a combination therapy (56.4% vs 15.2%, P <.01). After 6 months of treatment, in the group of patients under fgSRL as monotherapy, those patients with GH&PRL-PA had worse control compared to GH-PAs (29.4% vs 55.1%, P =.04). However, these differences in the rate of disease control between both groups disappeared when both received combination treatment with fgSRL and cabergoline. Conclusion In GH&PRL-PA, the biochemical control achieved with fgSRL as monotherapy is substantially worse than in patients harboring GH-PA, supporting the inclusion of cabergoline as first-line medical treatment in combination with fgSRLs in these subgroups of patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Endocrinology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
